Skip to main
SANA
SANA logo

Sana Biotechnology (SANA) Stock Forecast & Price Target

Sana Biotechnology (SANA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Sana Biotechnology has demonstrated a positive outlook based on significant advancements in its proprietary cell engineering programs, with increased probabilities of success for various platforms, notably the T1D and AID platforms, reflecting strong therapeutic potential. The favorable safety profile and sustained efficacy of its UP421 program, alongside promising data from mouse studies, bolsters confidence in the company’s HIP-technology's long-term viability and effectiveness. Overall, these developments, combined with updated financial models indicating increased probabilities of success for several product candidates, underpin a robust foundation for Sana Biotechnology's future growth prospects.

Bears say

Sana Biotechnology Inc. faces a significant financial outlook marked by anticipated substantial operating losses for the foreseeable future, indicating potential challenges in achieving profitability. The company's research and development expenses are higher than estimated, coupled with a projected need for approximately $1.1 billion to $1.4 billion in additional financing through 2040 to maintain operations. Furthermore, various risks, including safety concerns in clinical programs, regulatory challenges, and intense market competition, could exacerbate the negative impact on the company's stock performance, regardless of operational achievements.

Sana Biotechnology (SANA) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sana Biotechnology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sana Biotechnology (SANA) Forecast

Analysts have given Sana Biotechnology (SANA) a Buy based on their latest research and market trends.

According to 8 analysts, Sana Biotechnology (SANA) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sana Biotechnology (SANA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.